RE:RE:RE:JP Morgan healthcare conferenceShould read: January 11, 2025 - Eli Lilly and Company is in advanced talks to acquire Phase 1/2 biotechnology company Scorpion Therapeutics for $2.5 billion, the Financial Times reported on Friday, citing people briefed on the negotiations.
https://breakingthenews.net/Article/Eli-Lilly-said-to-be-in-talks-to-buy-Scorpion-Therapeutics-for-dollar2.5B/63336732
The deal is expected to be closed in the coming days before a healthcare conference in San Francisco organized by JPMorgan Chase, Eli Lilly's financial advisor, but it is not guaranteed, the sources told the media outlet. Scorpion's Phase1/2 P13K inhibitor STX-478, ia an oral, small molecule, once-daily, mutant-selective, allosteric PI3Kα inhibitor, with anti-tumor activity observed in multiple cancer types, including HR+/HER2- breast cancer (BC), gynecological tumors, and other solid tumors.
In September 2024, Scorpion detailed early data on targeted breast cancer, as it seeks to challenge Roche and Novartis for this cancer space. At the same time, Scorpion also announced that enrollment is in their study is ongoing including combinations with fulvestrant +/- CDK4,6 inhibitors in breast cancer, which are combination therapies that both Roche and Pfizer are pursuing.
https://www.roche.com/media/releases/med-cor-2023-12-05
ONCY has positioned reovirus as a follow-on therapy for patients who have relapsed from first and second line estrogen (fulvestrant) and ADC therapies (ie. ENHERTU) as well as CDK 4/6 oral small molecule therapies, like Pfizer's IBRANCE. ONCY has targeted the breast cancer space that currently has an unmet medical treatment need in the breast cancer drug treatment continuum.
Independent of this news, early research has demonstrated that inhibition of PI3K/Akt activation increases reovirus synthesis and yield.